Immunomodulatory minicells and methods of use
The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells.
1. A bacterial minicell comprising a cholesterol-dependent cytolysin protein, wherein said bacterial minicell does not display an antibody or other molecule comprising an Fc region of an antibody.
2. The bacterial minicell of claim 1 , wherein the bacterial minicell is a Th1 immunomodulatory minicell capable of producing a Th1 cytokine.
3. The bacterial minicell of claim 2 , wherein the Th1 cytokine is selected from the group consisting of IL-2, GMCSF, IL-12p40, IL-12p70, IL-18, TNF-α, and IFN-γ.
4. The bacterial minicell of claim 2 , wherein the Th1 immunomodulatory minicell is engineered to express or contain one or more immunomodulatory nucleic acids capable of stimulating endosome-localized Toll-like receptors 3, 7, 8, or 9.
5. The bacterial minicell of claim 1 , wherein the bacterial minicell further comprises an endosomal escape protein.
6. The bacterial minicell of claim 5 , wherein the endosomal escape protein is listeriolysin O (LLO).
7. The bacterial minicell of claim 1 , wherein the cholesterol-dependent cytolysin protein is present in the bacterial minicells in an amount capable of killing mammalian cells when the bacterial minicells contact the mammalian cell.
8. The bacterial minicell of claim 1 , wherein the cholesterol-dependent cytolysin protein is selected from the group consisting of listeriolysin O, listeriolysin O L461T, listeriolysin O E247M, listeriolysin O D320K, listeriolysin O E247M, listeriolysin O D320K, listeriolysin O L461T, streptolysin O, streptolysin O c, streptolysin O e, sphaericolysin, anthrolysin O, cereolysin, thuringiensilysin O, weihenstephanensilysin, alveolysin, brevilysin, butyriculysin, tetanolysin O, novyilysin, lectinolysin, pneumolysin, mitilysin, pseudopneumolysin, suilysin, intermedilysin, ivanolysin, seeligeriolysin O, vaginolysin, perfringolysin O, and pyolysin.
9. The bacterial minicell of claim 1 , wherein the cholesterol-dependent cytolysin protein is perfringolysin O.
10. The bacterial minicell of claim 1 , wherein the cholesterol-dependent cytolysin protein comprises an amino acid sequence according to SEQ ID NO: 1.
11. The bacterial minicell of claim 1 , wherein the bacterial minicell further comprises invasin displayed on the surface of the bacterial minicells, wherein the invasin is from Yersinia pseudotuberculosis.
12. The bacterial minicell of claim 1 , wherein the bacterial minicell further comprises a Th2 cytokine, wherein the Th2 cytokine is selected from the group consisting of IL-1α, IL-1β, IL-4, IL-5, IL-6, IL-10, and IL-13.
13. The bacterial minicell of claim 1 , wherein the bacterial minicell further comprises a phospholipase, wherein the phospholipase is selected from the group consisting of PC-PLC and PI-PLC.
14. The bacterial minicell of claim 1 , wherein the bacterial minicell further comprises one or more biologically active compounds, wherein the biologically active compounds are selected from the group consisting of small molecules, nucleic acids, polypeptides, radioisotope, lipids, lipopolysaccharides, and any combination of the foregoing.
15. The bacterial minicell of claim 1 , wherein the bacterial minicell further comprises an exogenous polypeptide that is not a protein toxin.
16. A composition comprising a bacterial minicell according to claim 1 and a physiologically acceptable carrier.
17. The composition of claim 13 , wherein the composition is formulated as a dry or liquid composition.
18. The composition of claim 13 that comprises minicell-producing viable parental cell contamination of less than 1 in 10 5 minicells.
19. A pharmaceutical composition comprising a bacterial minicell according to claim 1 and a pharmaceutically acceptable carrier.
20. The pharmaceutical composition of claim 19 that comprises minicell-producing viable parental cell contamination of less than 1 in 10 10 minicells.
21. The pharmaceutical composition of claim 19 , wherein the composition is formulated as a dry or liquid composition.
22. The pharmaceutical composition of claim 19 , wherein the composition is formulated as a liquid composition for parental administration to a subject.